Phase I/IB Trial of Eribulin and Everolimus in Patients With Triple Negative Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Eribulin (Primary) ; Everolimus (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 08 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 06 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 06 Oct 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.